The “Nuclear Imaging Market” report 2020 covers all the significant developments which are recently being adopted across the global market. The prime objective of the Nuclear Imaging market report is to provides an in-depth analysis of all market dynamics including drivers and restraints, and trends, and opportunities. The Nuclear Imaging market report covers both the demand and supply aspects of the market. The report also highlighted the future trends in the Nuclear Imaging market that will impact the demand during the forecast period.
Scope of the Report:
Nuclear medicine imaging procedures are non-invasive, with the exception of intravenous injections, and are usually painless medical tests that help physicians diagnose and evaluate medical conditions. These imaging scans use radioactive materials called radiopharmaceuticals or radiotracers. These radiopharmaceuticals are used in diagnosis and therapeutics. They are small substances that contain a radioactive substance that is used in the treatment of cancer, cardiac and neurological disorders.
Get a Sample Copy of the Report - https://www.industryresearch.co/enquiry/request-sample/13999574
Some of the Top Key Players of Nuclear Imaging Market Report Are:
- Market Dynamics – Drivers, Restraints, and Opportunities
- Market Segmentation – Types, Applications, Regions, and Technology
- Market Trends
- Competitive Landscape
- SWOT Analysis and Porter’s Five Forces Analysis
For More Information or Query or Customization Before Buying, Visit at - https://www.industryresearch.co/enquiry/pre-order-enquiry/13999574
Key Market Trends:
Oncology is Expected to hold its Highest Market Share in PET Applications
In the PET Applications segment, oncology is expected to have the largest market size and is expected to witness a CAGR of 6.35% during the forecast period.
The prevalence of various types of cancer has shown a significant rise over the past two decades. According to the statistics of Lymphoma Research Foundation, each year, more than 100,000 people are diagnosed with lymphoma, and nearly one million people in the United States are living with, or are in remission from, lymphoma. It is the third-most common cancer in children. According to the Global Burden of Disease - 2013 study, 725,000 people had Hodgkin’s lymphoma, and 24,000 died due to this, in 2013. 2.96 million people had non-Hodgkin’s lymphoma, and 226,000 died due to this, in 2013.
The FDG-PET/CT is more sensitive than contrast-enhanced CT scan in the staging of several types of lymphoma or in detecting tumor dissemination in several solid cancers, such as breast cancer, lung cancer, and colon cancer.
In the field of oncology, the PET (positron emission tomography) uses FDG (18Fluorine-2-fluoro-2-Deoxy-d-glucose) as the radiopharmaceutical, as it demonstrates the increased metabolism by malignant cells, when compared to that of normal cells. Furthermore, there is continuous technological progress in the field of image generation. The introduction of sophisticated software to use PET scan as a biomarker has facilitated new ways to calculate new prognostic markers, such as the metabolic tumor volume (MTV) and the total amount of tumor glycolysis (TLG). The 18F-fluorodeoxyglucose (18F-FDG) has high sensitivity, but it is not tumor specific. This technique can be used for the imaging of lung cancer, lymphoma, head and neck tumors, breast cancer, esophageal cancer, colorectal cancer, and urinary tract tumors. Hence, all the aforementioned technological advancements are expected to drive growth in this segment of the market studied, over the forecast period.
North America Domainates the Market and is Expected to do the Same in the Forecast Period
North America is projected to account for the largest share of the market, due to the advancements in technology, including hybrid imaging, the introduction of new radiopharmaceuticals for diagnosis, and the development of molecular imaging.
In 2016, the AMIPA (American Medical Isotope Production Act) and the DOE/NNSA (Department of Energy) established a Uranium Lease and Take-Back (ULTB) program in the United States. Under this program, the DOE/NNSA makes LEU (Low Enriched Uranium) available through lease contracts for the irradiation and production of Mo99 for medical uses. The AMIPA not only promotes the domestic production of Mo-99, but also aims to replace the role of HEU (High Enriched Uranium) in the production of medical radioactive isotopes.
Moreover, Canada is one of the largest producers of Technetium-99m. With the use of Tc-99m in radiopharmaceuticals, the market is expected to grow at a tremendous rate in Canada. It is also combined with a variety of biologically active molecules to perform non-invasive, real-time imaging of the human body.
Furthermore, there has been increasing awareness among people in this region about nuclear medicine treatment and diagnosis, which, in turn, has increased the prescriptions by physicians. This is expected to trigger the growth of the market.
The Report Covers:
- Comprehensive research methodology of Nuclear Imaging market
- In-depth analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global sleep aid market
- Insights about market determinants which are stimulating the global Nuclear Imaging market
- Detailed and extensive market segments with regional distribution of forecasted revenues
- Extensive profiles and recent developments of market players Companies Mentioned
Purchase this Report (Price 4250 USD for single user license) - https://www.industryresearch.co/purchase/13999574
Detailed TOC of Nuclear Imaging Market Report 2020-2024:
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Prevalence of Cancer and Cardiac Disorders
4.2.2 Increase in Technological Advancements
4.2.3 Growth in Applications of Nuclear Medicine and Imaging
4.3 Market Restraints
4.3.1 Regulatory Issues
4.3.2 Lack of Reimbursement
4.4 Industry Attractiveness - Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 By Equipment
5.1.2 By Radioisotope
18.104.22.168 By Diagnostic Technology
22.214.171.124.1 SPECT Radioisotopes
126.96.36.199.1.1 Technetium-99m (TC-99m)
188.8.131.52.1.2 Thallium-201 (TI-201)
184.108.40.206.1.3 GalliumÂ (Ga-67)
220.127.116.11.1.4 Iodine (I-123)
18.104.22.168.1.5 Other SPECT Radioisotopes
22.214.171.124.2 PET Radioisotopes
126.96.36.199.2.1 Fluorine-18 (F-18)
188.8.131.52.2.2 Rubidium-82 (RB-82)
184.108.40.206.2.3 Other PET Radioisotopes
5.2 By Application
5.2.1 SPECT Applications
220.127.116.11 Other SPECT Applications
5.2.2 PET Applications
18.104.22.168 Other PET Applications
5.3.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.3.4 Middle East & Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle East & Africa
5.3.5 South America
126.96.36.199 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bracco Imaging SpA
6.1.2 Cardinal Health Inc.
6.1.3 GE Healthcare
6.1.4 Koninklijke Philips NV
6.1.5 Siemens Healthineers
6.1.7 CMR NAVISCAN (GAMMA MEDICA INC.)
6.1.8 Nordion (Canada) Inc.
6.1.9 NTP Radioisotopes SOC
6.1.10 Toshiba Medical Systems Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Name: Ajay More
Phone: US +14242530807/ UK +44 20 3239 8187
Email: [email protected]
Our Other Reports: